Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALLKOTCMKTS:EVTCYNASDAQ:SDGRNASDAQ:TGTXNASDAQ:TPTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALLKAllakos$0.33$0.33$0.22▼$1.56$29.74M0.151.20 million shsN/AEVTCYEvotec$4.20-3.2%$4.13$14.22▼$26.57$1.39B0.982,407 shs61,993 shsSDGRSchrodinger$20.96$22.66$16.60▼$28.47$1.55B1.58914,852 shs348,387 shsTGTXTG Therapeutics$37.20+2.5%$36.77$16.65▼$46.48$5.83B1.912.92 million shs681,323 shsTPTXTurning Point Therapeutics$76.01$75.83$23.77▼$82.20$3.81B-0.181.14 million shs4,322 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALLKAllakos0.00%0.00%0.00%+4.48%-56.70%EVTCYEvotec0.00%+0.96%+2.44%+37.25%-15.15%SDGRSchrodinger0.00%+1.70%-12.08%+16.25%+4.28%TGTXTG Therapeutics0.00%+1.31%-5.34%-0.40%+97.98%TPTXTurning Point Therapeutics0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALLKAllakos2.8748 of 5 stars3.10.00.04.70.02.51.3EVTCYEvotecN/AN/AN/AN/AN/AN/AN/AN/ASDGRSchrodinger2.7933 of 5 stars3.42.00.00.02.92.50.6TGTXTG Therapeutics3.2988 of 5 stars1.41.00.03.52.72.51.9TPTXTurning Point TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALLKAllakos 2.25Hold$2.00507.72% UpsideEVTCYEvotec 0.00N/AN/AN/ASDGRSchrodinger 2.75Moderate Buy$33.2558.64% UpsideTGTXTG Therapeutics 2.80Moderate Buy$40.809.68% UpsideTPTXTurning Point Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest TGTX, EVTCY, SDGR, ALLK, and TPTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/3/2025SDGRSchrodingerMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageEqual Weight$28.004/16/2025SDGRSchrodingerKeyCorpSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$30.00 ➝ $32.00(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALLKAllakosN/AN/AN/AN/A$1.93 per shareN/AEVTCYEvotec$572.16M2.42$0.04 per share105.53$2.52 per share1.67SDGRSchrodinger$230.49M6.67N/AN/A$5.78 per share3.63TGTXTG Therapeutics$386.39M15.28$0.12 per share306.10$1.43 per share26.01TPTXTurning Point Therapeutics$30.83M123.46N/AN/A$15.84 per share4.80Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALLKAllakos-$185.70M-$1.32N/AN/AN/AN/A-140.87%-86.22%8/6/2025 (Estimated)EVTCYEvotec$7.14M$0.4110.24∞N/A20.85%16.02%7.81%N/ASDGRSchrodinger-$187.12M-$2.63N/AN/AN/A-83.39%-44.74%-26.29%7/30/2025 (Estimated)TGTXTG Therapeutics$23.38M$0.24155.0037.20N/A10.13%18.88%7.05%8/5/2025 (Estimated)TPTXTurning Point Therapeutics-$236.55M-$6.90N/AN/AN/AN/A-37.45%-35.62%N/ALatest TGTX, EVTCY, SDGR, ALLK, and TPTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/30/2025Q2 2025SDGRSchrodinger-$0.83N/AN/AN/A$52.03 millionN/A5/7/2025Q1 2025SDGRSchrodinger-$0.81-$0.82-$0.01-$0.82$54.60 million$59.55 million5/7/2025Q1 2025TGTXTG Therapeutics$0.19$0.03-$0.16$0.03$117.07 million$120.86 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALLKAllakosN/AN/AN/AN/AN/AEVTCYEvotecN/AN/AN/AN/AN/ASDGRSchrodingerN/AN/AN/AN/AN/ATGTXTG TherapeuticsN/AN/AN/AN/AN/ATPTXTurning Point TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALLKAllakosN/A6.086.08EVTCYEvotec0.532.572.50SDGRSchrodingerN/A3.453.45TGTXTG Therapeutics1.034.023.04TPTXTurning Point TherapeuticsN/A16.8316.83Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALLKAllakos84.64%EVTCYEvotecN/ASDGRSchrodinger79.05%TGTXTG Therapeutics58.58%TPTXTurning Point Therapeutics90.33%Insider OwnershipCompanyInsider OwnershipALLKAllakos16.12%EVTCYEvotecN/ASDGRSchrodinger8.60%TGTXTG Therapeutics10.64%TPTXTurning Point Therapeutics8.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALLKAllakos19090.38 million74.94 millionOptionableEVTCYEvotec4,200330.22 millionN/ANot OptionableSDGRSchrodinger79073.38 million67.07 millionOptionableTGTXTG Therapeutics290158.76 million141.86 millionOptionableTPTXTurning Point Therapeutics25050.07 million45.77 millionNot OptionableTGTX, EVTCY, SDGR, ALLK, and TPTX HeadlinesRecent News About These CompaniesTurning Point Therapeutics Inc (TPTX) - Investing.comJune 26, 2025 | investing.comBMS sets up Roche, Pfizer rivalry with Turning Point takeoverMay 20, 2025 | pharmaphorum.comPDigging Into Turning Point USA’s Role in the Trump 2024 Ground GameOctober 8, 2024 | talkingpointsmemo.comTTurning Point of Tampa Now In-Network with Blue Cross Blue Shield InsuranceSeptember 29, 2024 | markets.businessinsider.comDigital therapeutics at a turning point: What we heard at DTx EastSeptember 14, 2024 | pharmaphorum.comPPTC Therapeutics, Inc. (PTCT) Q2 2024 Earnings Call TranscriptAugust 9, 2024 | seekingalpha.comTG Therapeutics, Inc. (TGTX) Q2 2024 Earnings Call TranscriptAugust 6, 2024 | seekingalpha.comViking Therapeutics, Inc. (VKTX) Q2 2024 Earnings Call TranscriptJuly 25, 2024 | seekingalpha.comGlass System in Turning Point ResidenceApril 2, 2024 | archdaily.comABid to remove prosecutors sets up turning point in Trump’s Georgia caseFebruary 19, 2024 | politico.comPTurning Point Brands Inc.February 17, 2024 | wsj.comAlzheimer’s: A Turning Point?February 12, 2024 | bbc.co.ukTurning Point Brands Inc (TPB)February 10, 2024 | investing.comCormorant Asset Management, LP's Net WorthFebruary 10, 2024 | benzinga.comSolving quadratic equations - EdexcelJanuary 15, 2024 | bbc.co.ukCOP15: A Turning Point for Investor Approaches to BiodiversityDecember 19, 2023 | morningstar.comMTurning Point USA: Are conservatives fighting back on campus?December 16, 2023 | bbc.comBBMS bet looking good as Augtyro approved in ROS1-positive NSCLCNovember 16, 2023 | thepharmaletter.comTPhD Study : Developing an AI-enabled point-of-care monitoring system to detect systemic concentration of therapeutics in bloodOctober 29, 2023 | ulster.ac.ukUA Turning Point for Japan-US Climate Cooperation?October 28, 2023 | thediplomat.comTNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTGTX, EVTCY, SDGR, ALLK, and TPTX Company DescriptionsAllakos NASDAQ:ALLK$0.33 0.00 (0.00%) As of 05/15/2025Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications. The company was incorporated in 2012 and is headquartered in San Carlos, California.Evotec OTCMKTS:EVTCY$4.20 -0.14 (-3.23%) As of 07/3/2025Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmers on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties. The EVT Innovate develops drug discovery projects, assets and platforms, both internally or through academic collaborations. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.Schrodinger NASDAQ:SDGR$20.96 0.00 (0.00%) Closing price 07/3/2025 03:29 PM EasternExtended Trading$21.04 +0.08 (+0.38%) As of 07/3/2025 04:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.TG Therapeutics NASDAQ:TGTX$37.20 +0.91 (+2.51%) Closing price 07/3/2025 03:25 PM EasternExtended Trading$36.94 -0.26 (-0.69%) As of 07/3/2025 04:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.Turning Point Therapeutics NASDAQ:TPTXTurning Point Therapeutics, Inc., a clinical-stage precision oncology biopharmaceutical company, engages in designing and developing therapies that target genetic drivers of cancer. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients. The company's lead drug candidate repotrectinib is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+ and NTRK+ advanced solid tumors. It also develops TPX-0022, a MET/SRC/CSF1R inhibitor, which is in Phase 1 SHIELD-1 clinical trial for patients with advanced solid tumors harboring genetic alterations in MET; TPX-0046, a RET inhibitor that is in 1/2 SWORD-1 clinical trial for patients with advanced solid tumors harboring RET genetic alterations; and TPX-0131, an ALK inhibitor, which is in Phase 1/2 FORGE-1 study for patient with advanced or metastatic TKI-pretreated ALK-positive NSCLC. Turning Point Therapeutics, Inc. was founded in 2013 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Correction Equals Opportunity in Domino’s Pizza Stock Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.